Harbour BioMed announced an update and advancement of its global strategic collaboration with AstraZeneca (AZN), originally established in March 2025. The collaboration aims to discover and develop next-generation biotherapeutics, including antibody-drug conjugates, ADCs, and T cell engagers, leveraging the knowledge of both companies. Under the terms of the agreement, AstraZeneca will continue to nominate discovery programs to Harbour BioMed each year over the next four years, reflecting the continued progress of the partnership, and will retain the option to license these programs for further development. Harbour BioMed will be eligible to receive option and option exercise fees, development and commercial milestone payments, plus tiered royalties on future net sales on such licensed programs. The economic terms are consistent with the financial framework established in March 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca plans $2B manufacturing investment in Maryland
- RFK told CDC to change website language on autism and vaccines, NYT reports
- Quantum Computing News: New Error Control Shift and New Site Plans Guide the Next Phase for Key Quantum Stocks
- IonQ Tells Congress Its Quantum Systems Are Moving Into Early Real-World Use
- AstraZeneca treatment of multiple myeloma granted orphan designation